These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38317525)

  • 41. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
    Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment patterns, adherence, and persistence among psoriasis patients treated with biologics in a real-world setting, overall and by disease severity.
    Murage MJ; Anderson A; Casso D; Oliveria SA; Ojeh CK; Muram TM; Merola JF; Zbrozek A; Araujo AB
    J Dermatolog Treat; 2019 Mar; 30(2):141-149. PubMed ID: 29799292
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
    He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
    Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adherence and resource use among psoriasis patients treated with biologics.
    Aleshaki JS; Cardwell LA; Muse ME; Feldman SR
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):609-617. PubMed ID: 30142007
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States.
    Armstrong AW; Patel M; Li C; Garg V; Mandava MR; Wu JJ
    J Dermatolog Treat; 2023 Dec; 34(1):2200870. PubMed ID: 37154473
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs.
    Murage MJ; Princic N; Park J; Malatestinic WN; Zhu B; Atiya B; Kern SA; Stenger KB; Sprabery AT; Ogdie A
    J Manag Care Spec Pharm; 2022 Feb; 28(2):206-217. PubMed ID: 35098751
    [No Abstract]   [Full Text] [Related]  

  • 48. Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ.
    Curmin R; Guillo S; De Rycke Y; Bachelez H; Beylot-Barry M; Beneton N; Chosidow O; Dupuy A; Joly P; Jullien D; Richard MA; Viguier M; Sbidian E; Paul C; Mahé E; Tubach F;
    J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2101-2112. PubMed ID: 35793473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Insurance Coverage of Biologics for Moderate-to-Severe Psoriasis: A Retrospective, Observational 5-Year Chart Review.
    Abdelnabi M; Patel A; Rengifo-Pardo M; Ehrlich A
    Am J Clin Dermatol; 2016 Aug; 17(4):421-4. PubMed ID: 27283586
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival rates of systemic interventions for psoriasis in the Western Japan Psoriasis Registry: A multicenter retrospective study.
    Yanase T; Tsuruta N; Yamaguchi K; Ohata C; Ohyama B; Katayama E; Sugita K; Kuwashiro M; Hashimoto A; Yonekura K; Higashi Y; Murota H; Koike Y; Matsuzaka Y; Kikuchi S; Hatano Y; Saito K; Takahashi K; Miyagi T; Kaneko S; Ota M; Harada K; Morizane S; Ikeda K; Furue M; Nakahara T; Okazaki F; Sasaki N; Okada E; Yoshida Y; Ito K; Imafuku S
    J Dermatol; 2023 Jun; 50(6):753-765. PubMed ID: 36786158
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data.
    Sugiyama N; Kawahito Y; Fujii T; Atsumi T; Murata T; Morishima Y; Fukuma Y
    Clin Ther; 2016 Jun; 38(6):1359-1375.e1. PubMed ID: 27101816
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Healthcare resource utilization, total costs, and comorbidities among patients with myotonic dystrophy using U.S. insurance claims data from 2012 to 2019.
    Howe SJ; Lapidus D; Hull M; Yeaw J; Stevenson T; Sampson JB
    Orphanet J Rare Dis; 2022 Feb; 17(1):79. PubMed ID: 35197080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice.
    Ding B; Kallenbach L; Slipski L; Wilk A; O'Brien D; Guranlioglu D
    Int J Chron Obstruct Pulmon Dis; 2020; 15():775-786. PubMed ID: 32346288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Japanese guidance for use of biologics for psoriasis (the 2019 version).
    Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M;
    J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
    Al-Janabi A; Alabas OA; Yiu ZZN; Foulkes AC; Eyre S; Khan AR; Reynolds NJ; Smith CH; Griffiths CEM; Warren RB;
    JAMA Dermatol; 2024 Jan; 160(1):71-79. PubMed ID: 38055239
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
    Grabner M; Boytsov NN; Huang Q; Zhang X; Yan T; Curtis JR
    Arthritis Res Ther; 2017 May; 19(1):92. PubMed ID: 28506320
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Mieno M; Ohtsuki M
    J Dermatol; 2020 Jan; 47(1):33-40. PubMed ID: 31696543
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims.
    Senna M; Ko J; Tosti A; Edson-Heredia E; Fenske DC; Ellinwood AK; Rueda MJ; Zhu B; King B
    Adv Ther; 2021 Sep; 38(9):4646-4658. PubMed ID: 34292518
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Real-world retrospective analysis of patient characteristics, healthcare resource utilization, costs, and treatment patterns among unvaccinated adults with COVID-19 diagnosed in outpatient settings in the United States.
    Scott A; Chambers R; Reimbaeva M; Atwell J; Baillon-Plot N; Draica F; Tarallo M
    J Med Econ; 2022; 25(1):287-298. PubMed ID: 35114896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.